Abstract Each year, about 5–6 cases out of 100,000 people are diagnosed with primary
malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma …

Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM)
despite the fact that approximately half of treated patients have temozolomide resistance …

Background Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its
ligand (PD-L1) showed activity in several cancer types. Methods We performed …

Simple Summary Numerous mechanisms of glioblastoma (GBM) radioresistance have been
identified but have not yet resulted in development of effective radiosensitizer that can …

Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that
needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict …

Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …

Purpose Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor
(HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical …

The different drugs and medical devices, which are commercialized or under industrial
development for glioblastoma treatment, are reviewed. Their different modes of action are …

The subventricular zone (SVZ) lines the lateral ventricles and represents the origin of neural
and some cancer stem cells. Tumors contacting the SVZ may be more invasive with higher …

Tumours of the central nervous system are intrinsically more dangerous than tumours at
other sites, and in particular, brain tumours are responsible for 3% of cancer deaths in the …